AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30561610 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injection
Number of subjects: 129
Study 30561610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 28124736 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 2 L/kg/min oxygen therapy
Number of subjects: 142
Study 28124736 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) at 7 cmH2O
Number of subjects: 142
Study 26103129 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g daily for 8 weeks)
Number of subjects: 74
Study 26103129 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 (200 mg daily for 8 weeks)
Number of subjects: 74
Study 26103129 — intervention group
Group type: COMPARATOR
Intervention: Control (4 g olive oil daily for 8 weeks)
Number of subjects: 74
Study 25386520 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and locally delivered propolis
Number of subjects: 20
Study 25386520 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study 20236716 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/d)
Number of subjects: 42
Study 19268686 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg TTX
Number of subjects: 45
Study 19268686 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg TTX
Number of subjects: 45
Study 19268686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17106937 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mug CIFN three times per week for 52 wk plus ribavirin 800 to 1200 mg daily for 52 wk
Number of subjects: 45
Study 17106937 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mug CIFN three times per week for 52 wk plus ribavirin 800 to 1200 mg daily for 52 wk
Number of subjects: 45
Study 17106937 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN in combination with ribavirin (both doses)
Number of subjects: 45
Study 17106937 — intervention group
Group type: COMPARATOR
Intervention: CIFN in combination with ribavirin
Number of subjects: 45
Study 14702423 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily
Number of subjects: 1484
Study 14702423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment (specific dietary fatty acids not detailed)
Number of subjects: 185
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weight
Number of subjects: 185
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 185
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 plasma 22:5n-6
Number of subjects: 185
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 red cell membrane 20:3n-9
Number of subjects: 185
Study 11724461 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of smokers in the household
Number of subjects: 185
Study 9215816 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1523
Study 8020175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone administration (Group A)
Number of subjects: 303
Study 8020175 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutical application of ceftriaxone (Group B)
Number of subjects: 303
Study 8020175 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (Group C)
Number of subjects: 303
Study 8020175 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Group D)
Number of subjects: 303
Study 8020175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone administration (Group A) - Newborns
Number of subjects: 303
Study 8020175 — intervention group
Group type: COMPARATOR
Intervention: Therapeutical application of ceftriaxone (Group B) - Newborns
Number of subjects: 303
Study 3300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate 20 mg (3 X 20 mg/day)
Number of subjects: 12
Study 3300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate 50 mg (once daily)
Number of subjects: 12
Study 3300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (3 X 20 mg/day)
Number of subjects: 12
Study 28117541 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of skills assessment with feedback (group B)
Number of subjects: 32
Study 28117541 — intervention group
Group type: COMPARATOR
Intervention: Two sessions of additional skills training (group A)
Number of subjects: 32
Study 27059970 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified stents for 3 days (Group A)
Number of subjects: 77
Study 27059970 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified stents for 2 days (Group B)
Number of subjects: 77
Study 27059970 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation (Group C)
Number of subjects: 77
Study 27059970 — intervention group
Group type: COMPARATOR
Intervention: Regular stents for 2 days (Group D)
Number of subjects: 77
Study 24102964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (10 μg/kg per min)
Number of subjects: 56
Study 22427290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 120
Study 22427290 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 120
Study 22427290 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Cinnarizine and Propranolol
Number of subjects: 120
Study 21953602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute cortisol (30 mg hydrocortisone)
Number of subjects: 20
Study 21953602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18310602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet combined with low doses of vitamin D sterols
Number of subjects: 444
Study 18310602 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet alone
Number of subjects: 444
Study 17323592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin (dual antiplatelet therapy)
Number of subjects: 0
Study 17323592 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (monotherapy)
Number of subjects: 0
Study 12891166 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise as part of cardiac rehabilitation
Number of subjects: 0
Study 12891166 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0
Study 12891166 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded conditioning program
Number of subjects: 0
Study 12891166 — intervention group
Group type: COMPARATOR
Intervention: Exercise rehabilitation
Number of subjects: 0
Study 10923282 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone alone (0.5-3.0 mg/day for one cycle)
Number of subjects: 0
Study 10923282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (30 micrograms) + Drospirenone (2 mg or 3 mg for three cycles)
Number of subjects: 0
Study 10923282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (30 micrograms) + Drospirenone (3 mg)
Number of subjects: 0
Study 10923282 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (30 micrograms) + Desogestrel (150 micrograms) (Marvelon)
Number of subjects: 0
Study 8828991 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 20
Study 1424207 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 1.2 IU/kg/week for 18 months
Number of subjects: 22
Study 1424207 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 22
Study 4096058 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned by situation 'consulting hours hypertension'
Number of subjects: 84
Study 4096058 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamically oriented differential therapy
Number of subjects: 84
Study 30293411 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (2000 single shocks; strength, 1.5 to 3.0 bar; shock frequency, 9 to 12 Hz)
Number of subjects: 51
Study 30293411 — intervention group
Group type: COMPARATOR
Intervention: Physical treatments (acupuncture, ultrasonic wave, microwave therapy)
Number of subjects: 51
Study 30293411 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-groups comparison
Number of subjects: 51
Study 30134289 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL-based regimen for 10 weeks
Number of subjects: 40
Study 30134289 — intervention group
Group type: COMPARATOR
Intervention: Continuation of nonintegrase inhibitor regimen
Number of subjects: 40
Study 28096711 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy (HILT)
Number of subjects: 72
Study 28096711 — intervention group
Group type: COMPARATOR
Intervention: Sham Laser
Number of subjects: 72
Study 24356594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy (INT)
Number of subjects: 1441
Study 22883020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane using the anesthetic-conserving device (ACD)
Number of subjects: 0
Study 22883020 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation with propofol
Number of subjects: 0
Study 22883020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane using the ACD
Number of subjects: 0
Study 20308973 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola Rosea
Number of subjects: 14
Study 20308973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17986941 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 3 days after burr-hole surgery (Group A)
Number of subjects: 84
Study 17986941 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with head of bed elevated to 30 to 40 degrees for 3 days after burr-hole surgery (Group B)
Number of subjects: 84
Study 15206003 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a mean dose of 0.25‐0.3 mg/kg body weight
Number of subjects: 99
Study 15206003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 15206003 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 99
Study 11773299 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based adjuvant chemotherapy
Number of subjects: 6754
Study 11773299 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) or anthracycline-based regimens
Number of subjects: 6754
Study 9649976 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day lofexidine treatment
Number of subjects: 61
Study 9649976 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day lofexidine treatment
Number of subjects: 61
Study 9649976 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 61
Study 9649976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lofexidine regimens
Number of subjects: 61
Study 9649976 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 61
Study 7972809 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal duplex Doppler sonography
Number of subjects: 32
Study 2637078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 5 Gy
Number of subjects: 90
Study 2637078 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.15 x 2 Gy
Number of subjects: 90
Study 2637078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 x 2.5 Gy
Number of subjects: 90
Study 2637078 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 5 Gy
Number of subjects: 90
Study 2637078 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (general)
Number of subjects: 90
Study 1095162 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30
Study 1095162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30
Study 1095162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study 31801584 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgraded maternity waiting homes (MWHs) + religious/community leader training
Number of subjects: 3840
Study 31801584 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader training alone
Number of subjects: 3840
Study 31801584 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3840
Study 28268215 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine oral lyophilisate (bup-lyo)
Number of subjects: 36
Study 28268215 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine sublingual tablets (bup-SL)
Number of subjects: 36
Study 26051445 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Resistance Training (CRT)
Number of subjects: 121
Study 26051445 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 121
Study 26051445 — intervention group
Group type: COMPARATOR
Intervention: Standard Follow-up (CON)
Number of subjects: 121
Study 23224689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 220
Study 23224689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 21708823 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise for 8 weeks
Number of subjects: 19
Study 19349387 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE-led management
Number of subjects: 198
Study 19349387 — intervention group
Group type: COMPARATOR
Intervention: MD-managed patients
Number of subjects: 198
Study 19349387 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite analysis of both CRE and MD data
Number of subjects: 198
Study 16765759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy (target international normalised ratio of 2.0-3.0)
Number of subjects: 6706
Study 16765759 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg per day) plus aspirin (75-100 mg per day)
Number of subjects: 6706
Study 16765759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy (for patients already receiving treatment at study entry)
Number of subjects: 6706
Study 16765759 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (for patients not on oral anticoagulation therapy at study entry)
Number of subjects: 6706
Study 15604228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Family Learning Approach (CFLA)
Number of subjects: 0
Study 15604228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11895463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary treatment with oestrogen (group 2)
Number of subjects: 24
Study 11895463 — intervention group
Group type: COMPARATOR
Intervention: No intracoronary treatment (group 1)
Number of subjects: 24
Study 10102427 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 million international units (mIU) of IFN‐alpha2a
Number of subjects: 97
Study 10102427 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 million international units (mIU) of IFN‐alpha2a
Number of subjects: 97
Study 10102427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 10102427 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha2a treatment
Number of subjects: 97
Study 7775507 — intervention group
Group type: EXPERIMENTAL
Intervention: SkinTemp dressing (covered for 7 days)
Number of subjects: 8
Study 7775507 — intervention group
Group type: COMPARATOR
Intervention: Xeroform dressing (covered for 24 hours)
Number of subjects: 8
Study 2290737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Care Program
Number of subjects: 0
Study 2290737 — intervention group
Group type: COMPARATOR
Intervention: Usual hospitalization
Number of subjects: 0
Study 363490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea or insulin treatment
Number of subjects: 0
Study 363490 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose load
Number of subjects: 0
Study 363490 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment with sulfonylurea or insulin
Number of subjects: 0
Study 31831167 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care educational video
Number of subjects: 111
Study 31831167 — intervention group
Group type: COMPARATOR
Intervention: Non‐directive cancer center video
Number of subjects: 111
Study 31831167 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care services utilization (historical data)
Number of subjects: 111
Study 30400757 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 8
Study 28079621 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional education by the IBD nurse with an information brochure and vaccination card
Number of subjects: 505
Study 28079621 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice
Number of subjects: 505
Study 26067585 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg twice daily)
Number of subjects: 194
Study 26067585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg twice daily)
Number of subjects: 194
Study 26067585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 23629145 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional diet or meal replacements
Number of subjects: 113
Study 23629145 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers lost above the median (‐1.67%) at month 4
Number of subjects: 113
Study 21427652 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene
Number of subjects: 111
Study 21427652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 19995115 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 40
Study 19995115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 17241414 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTOX (50 U)
Number of subjects: 10
Study 17241414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (150 U)
Number of subjects: 10
Study 15493734 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infant formula
Number of subjects: 34
Study 15493734 — intervention group
Group type: COMPARATOR
Intervention: Standard term infant formula
Number of subjects: 34
Study 11447547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during surgery (T)
Number of subjects: 48
Study 11447547 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet use during surgery (NT)
Number of subjects: 48
Study 9756585 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intra-arterial fibrinolysis with Urokinase (100,000 to 900,000 IU) administered over 10 to 90 minutes
Number of subjects: 17
Study 9756585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrinolytics)
Number of subjects: 17
Study 7846309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (400 mg of soil/day)
Number of subjects: 9
Study 7846309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (2.0 g of soil/day)
Number of subjects: 9
Study 7846309 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 9
Study 2898400 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran (Imferon) administered by total dose infusion (TDI) at high dose
Number of subjects: 623
Study 2898400 — intervention group
Group type: COMPARATOR
Intervention: Iron dextran (Imferon) administered by total dose infusion (TDI) at low dose
Number of subjects: 623
Study 31452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatments for non-communicable diseases (NCD)
Number of subjects: 451
Study 31452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline frequency of comorbidities
Number of subjects: 451
Study 31452382 — intervention group
Group type: EXPERIMENTAL
Intervention: Last visit frequency of comorbidities
Number of subjects: 451
Study 27956737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened beverage
Number of subjects: 30
Study 27956737 — intervention group
Group type: EXPERIMENTAL
Intervention: Monk fruit-sweetened beverage
Number of subjects: 30
Study 27956737 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevia-sweetened beverage
Number of subjects: 30
Study 27956737 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-sweetened beverage
Number of subjects: 30
Study 25225010 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy (three courses)
Number of subjects: 35
Study 23470571 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurectomy
Number of subjects: 44
Study 23470571 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 44
Study 21172596 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography interpretation by local lab
Number of subjects: 199
Study 19100967 — intervention group
Group type: COMPARATOR
Intervention: ADHD‐HI
Number of subjects: 197
Study 19100967 — intervention group
Group type: COMPARATOR
Intervention: ADHD‐C
Number of subjects: 197
Study 19100967 — intervention group
Group type: COMPARATOR
Intervention: ADHD‐I
Number of subjects: 197
Study 19100967 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 197
Study 17059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine injection into the endothoracic fascia (Group 2)
Number of subjects: 100
Study 17059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation (Group 3)
Number of subjects: 100
Study 17059933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of papaverine and carbon dioxide (Group 4)
Number of subjects: 100
Study 17059933 — intervention group
Group type: COMPARATOR
Intervention: No vasodilatory management (Group 1)
Number of subjects: 100
Study 15222594 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) program for 3 weeks
Number of subjects: 271
Study 15222594 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based program (CP2) for 4 weeks
Number of subjects: 271
Study 15222594 — intervention group
Group type: COMPARATOR
Intervention: Community-based program (CP1) for 6 weeks
Number of subjects: 271
Study 15222594 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) program
Number of subjects: 271